Life Therapeutics Limited

Life Therapeutics (ASX: LFE) today announced that the company has resolved to appoint an Independent Expert to provide an independent valuation on the proposed transaction with Kedrion S.p.A ("Kedrion"), pursuant to the terms announced on 30 July 2007. This will include an assessment of the value of LFE's equity stake in Kedrion.

Life Therapeutics (ASX: LFE) today provided details of an agreement (the "Agreement") with Kedrion S.p.A ("Kedrion"), a leading European speciality pharmaceutical company and Italy's largest fractionator, that will enable the company to deliver on its strategy to become a vertically integrated operator. Under the terms of the Agreement, Life Therapeutics will take up a 5.5% equity stake in Kedrion and will divest assets from its Life Sera business into a new joint venture company with Kedrion ("Newco").

On 19 March 2007 Life Therapeutics (ASX: LFE) (PNK: LFEFY) announced that it had entered into a non-binding Heads of Agreement with a European fractionator in relation to a proposed transaction. At that time, the company granted to the European fractionator exclusive negotiation rights up until 1 June 2007.

Life Therapeutics (ASX: LFE)(PNK: LFEFY) has signed a new two year contract to produce hyperimmune plasma for a major fractionator. The value of the contract ranges from a minimum of A$4M up to A$12M per year for two years.

Donor Computer System now rolled out to all Collection Centers ATLANTA - 11 October, 2006 - Life Therapeutics (ASX: LFE) has now successfully completed the computerisation of the 5 West Coast plasma collection centres.

Life Therapeutics (ASX: LFE)(PNK: LFEFY) announced today that it has completed the sale of the Frenchs Forest building for A$9.25m to a fund controlled by MacarthurCook Ltd (ASX: MCK).

Life Therapeutics (ASX: LFE) will supply Cangene Corporation with Anti-Anthrax plasma for Cangene to produce an Anti-Anthrax hyperimmune for the U.S. Department of Health and Human Services.

Life Therapeutics (ASX: LFE) announced today that it has signed leases to open two new donor collection centers: one in Sacramento and the second in Long Beach in California. It is expected that these centers will become operational at the end of August 2006.

Life Therapeutics (ASX: LFE) announced today that it has exchanged contracts with MacarthurCook Ltd (ASX: MCK) for the sale of its Frenchs Forest building.

GammaCan International (OTCBB: GCAN), and Life Therapeutics (ASX: LFE) today announced a joint effort to develop VitiGam, an innovative anti-cancer product designed to target metastatic malignant melanoma patients with Stage III and IV disease, in connection with a grant to be provided by the BIRD Foundation.